MX338981B - Proteina de fusion robo1-fc y sus uso en el tratamiento de tumores. - Google Patents

Proteina de fusion robo1-fc y sus uso en el tratamiento de tumores.

Info

Publication number
MX338981B
MX338981B MX2012011822A MX2012011822A MX338981B MX 338981 B MX338981 B MX 338981B MX 2012011822 A MX2012011822 A MX 2012011822A MX 2012011822 A MX2012011822 A MX 2012011822A MX 338981 B MX338981 B MX 338981B
Authority
MX
Mexico
Prior art keywords
robo1
fusion protein
treating tumours
relates
recombinant protein
Prior art date
Application number
MX2012011822A
Other languages
English (en)
Other versions
MX2012011822A (es
Inventor
Francis Blanche
Pierre Fons
Béatrice Cameron
Tarik Dabdoubi
Frédérique Dol-Gleizes
Jean-Pascal Heraul
Catherine Prades
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42830780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX338981(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2012011822A publication Critical patent/MX2012011822A/es
Publication of MX338981B publication Critical patent/MX338981B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a una proteína recombinante Robo1-Fc y su uso para tratar las enfermedades en las que se sobreexpresan una proteína Slit, en particular cáncer. Se refiere igualmente a una composición que comprende tal proteína recombinante. Otro aspecto de la invención consiste en el uso de una molécula Robo1-Fc como una herramienta de diagnóstico para detectar la sobreexpresión de una molécula de la familia Slit en un paciente.
MX2012011822A 2010-04-14 2011-04-08 Proteina de fusion robo1-fc y sus uso en el tratamiento de tumores. MX338981B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1052829A FR2958936A1 (fr) 2010-04-14 2010-04-14 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
PCT/FR2011/050811 WO2011128561A1 (fr) 2010-04-14 2011-04-08 Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Publications (2)

Publication Number Publication Date
MX2012011822A MX2012011822A (es) 2012-11-12
MX338981B true MX338981B (es) 2016-05-06

Family

ID=42830780

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011822A MX338981B (es) 2010-04-14 2011-04-08 Proteina de fusion robo1-fc y sus uso en el tratamiento de tumores.

Country Status (26)

Country Link
US (1) US9493529B2 (es)
EP (1) EP2558489A1 (es)
JP (1) JP5858442B2 (es)
KR (1) KR20130059329A (es)
CN (1) CN102884076A (es)
AR (1) AR080891A1 (es)
AU (1) AU2011239839B2 (es)
BR (1) BR112012026020A2 (es)
CA (1) CA2796303A1 (es)
CL (1) CL2012002879A1 (es)
CR (1) CR20120508A (es)
DO (1) DOP2012000265A (es)
EA (1) EA201291044A1 (es)
EC (1) ECSP12012230A (es)
FR (1) FR2958936A1 (es)
GT (1) GT201200275A (es)
IL (1) IL222382A (es)
MA (1) MA34221B1 (es)
MX (1) MX338981B (es)
NI (1) NI201200155A (es)
PE (1) PE20130199A1 (es)
SG (1) SG184529A1 (es)
TN (1) TN2012000473A1 (es)
TW (1) TW201142024A (es)
UY (1) UY33334A (es)
WO (1) WO2011128561A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33833A (es) * 2010-12-23 2012-07-31 Sanofi Sa Proteína de fusión Robo1-Fc para su uso en el tratamiento del hepatocarcinoma
ES2714700T3 (es) 2012-01-05 2019-05-29 Boston Medical Ct Corp Señalización de SLIT-ROBO para el diagnóstico y el tratamiento de una enfermedad de riñón
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
CN109311949B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 储存分离基质的方法
WO2017194593A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
JP7018458B2 (ja) * 2017-06-02 2022-02-10 ファイザー・インク 組換えｒｏｂｏ２タンパク質、組成物、方法およびそれらの使用
EP3672992A4 (en) 2017-08-24 2021-05-19 Bar-Ilan University ROUNDABOUT FAMILY RECEPTOR INHIBITORS (ROBO) AND CORRESPONDING USES
US20220125879A1 (en) * 2019-02-27 2022-04-28 Daewoong Pharmaceutical Co., Ltd. Albumin-bound composition including lrrd2 of slit3 protein for prevention or treatment of bone-related diseases
CA3136663A1 (en) * 2019-04-23 2020-10-29 The Regents Of The University Of California Compositions and methods useful in promoting milk production

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
JP2003517262A (ja) * 1997-10-20 2003-05-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 神経誘導に含まれるポリペプチド及び核酸のファミリーであるｒｏｂｏ
JP2002510479A (ja) * 1998-04-02 2002-04-09 ライジェル・ファーマシューティカルズ・インコーポレイテッド コンパクトな構造の形成を引き起こすペプチド
AU2001283062A1 (en) * 2000-08-02 2002-02-13 The Johns Hopkins University Endothelial cell expression patterns
WO2003075860A2 (en) 2002-03-08 2003-09-18 Abgent, Inc. Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
EP2311468B1 (en) * 2003-08-08 2014-01-15 Perseus Proteomics Inc. Gene overexpressed in cancer
BRPI0507174A (pt) * 2004-01-28 2008-04-01 Syntonix Pharmaceuticals Inc proteìnas de fusão hormÈnio-fc (fsh-fc) heterodiméricas estimuladoras de folìculo para o tratamento da infertilidade
RU2466740C2 (ru) * 2006-04-05 2012-11-20 Эбботт Байотекнолоджи Лтд. Очистка антитела
CL2007003411A1 (es) 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
EP2599791A1 (en) * 2007-04-27 2013-06-05 Genentech, Inc. Potent, stable and non-immunosuppressive anti-CD4 antibodies
SG10201407388XA (en) 2007-08-29 2015-01-29 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof

Also Published As

Publication number Publication date
CL2012002879A1 (es) 2013-03-22
US9493529B2 (en) 2016-11-15
GT201200275A (es) 2014-01-24
BR112012026020A2 (pt) 2016-06-28
NI201200155A (es) 2013-02-05
IL222382A0 (en) 2012-12-31
WO2011128561A1 (fr) 2011-10-20
IL222382A (en) 2016-06-30
CN102884076A (zh) 2013-01-16
US20130039912A1 (en) 2013-02-14
FR2958936A1 (fr) 2011-10-21
PE20130199A1 (es) 2013-03-09
AR080891A1 (es) 2012-05-16
DOP2012000265A (es) 2013-02-28
KR20130059329A (ko) 2013-06-05
MX2012011822A (es) 2012-11-12
MA34221B1 (fr) 2013-05-02
ECSP12012230A (es) 2012-11-30
TW201142024A (en) 2011-12-01
CR20120508A (es) 2012-11-01
EA201291044A1 (ru) 2013-04-30
TN2012000473A1 (fr) 2014-01-30
JP2013523172A (ja) 2013-06-17
JP5858442B2 (ja) 2016-02-10
SG184529A1 (en) 2012-11-29
AU2011239839A1 (en) 2012-11-08
EP2558489A1 (fr) 2013-02-20
AU2011239839B2 (en) 2015-08-20
CA2796303A1 (fr) 2011-10-20
UY33334A (es) 2011-12-01

Similar Documents

Publication Publication Date Title
MX338981B (es) Proteina de fusion robo1-fc y sus uso en el tratamiento de tumores.
UA110473C2 (uk) Спосіб лікування раку за допомогою пухлиноасоційованого антигену, отриманого із цикліну d1
IN2012DN02081A (es)
BR112012016376A2 (pt) compostos de pirrolo-aminopirimida substituída
IN2012MN02591A (es)
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
EP2582722A4 (en) ANTIBODIES AGAINST GD2
MY171100A (en) Anti-ceacam5 antibodies and uses thereof
BR112014003477A2 (pt) composições imunoterapêuticas de levedura-muc1 e usos das mesmas
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
MX2013004897A (es) Anticuerpos y composiciones anti-her3.
WO2012068383A3 (en) ncRNA AND USES THEREOF
MX349004B (es) Nuevos compuestos.
GB201118656D0 (en) New compounds
PH12015500084A1 (en) Rspo3 binding agents and uses thereof
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
PH12015500392B1 (en) Antibody drug conjugates (adc) that bind to 158p1d7 proteins
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
MX2013001836A (es) Proteina de fusion de fc recombinante del quinto dominio tipo iii de fibronectina de ddc.
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.
TN2012000151A1 (en) Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer
MX2013002446A (es) Derivados de tetrahidropirrolopirazina sustituidos.

Legal Events

Date Code Title Description
FG Grant or registration